Blogs

Blogs

ASCOconnection.org is a forum for the exchange of views on topical issues in the field of oncology. The views expressed in the blogs, comments, and forums belong to the authors. They do not necessarily reflect the views or positions of the American Society of Clinical Oncology. Please read the Commenting Guidelines.

No Results.

"If we can provide chemotherapy services through a tele-chemotherapy model at smaller rural centers, why can’t we do the same for clinical trials?" asks Dr. Sabe Sabesan.
"Cancer research relevant to LMICs is a necessity, not a luxury," writes Dr. Khalid El Bairi, and early-career oncologists in LMIC settings can advance cancer research in their communities.
"If you are young researcher in an LMIC trying to launch your own career, I highly recommend building collaborations and networks with oncologists around the globe," said Dr. Khalid El Bairi.
Using bibliometrics, Dr. Khalid El Bairi identified a research gap in Morocco, and felt a responsibility to fill it.
I interviewed Dr. Lawrence with the hope that others will be inspired by his groundbreaking work in international trial design.
As we celebrate the 20th anniversary of World Cancer Day this February 4, it’s important to recognize that we are making progress in addressing cancer.
Dr. Linus T. Chuang outlines challenges and opportunities for global cancer care on World Cancer Research Day.
GLOBOCAN 2018 indicates a significant global increase in the numbers, incidence, and mortality rates, albeit significant differences in mortality amongst countries of different economic levels. 
ASCO's nearly 45,000 members practice in more than 150 countries, and continued progress against cancer will require every one of us, writes ASCO CMO Dr. Richard L. Schilsky.
Dr. Richard L. Schilsky describes ASCO's Targeted Agent and Profiling Utilization Registry (TAPUR) Study and similar independent studies worldwide.
A journal that aims to be the voice of global oncology has to publish work relating not only to differences in cancer biology due to risk factors, pathogenesis, and pharmacology, but also disparities arising from social, cultural, economic, and political resource-constraining issues.
Dr. Richard L. Schilsky outlines the Society's Target Agent and Profiling Utilization Registry (TAPUR) Study and similar international protocols. A global data sharing platform could greatly accelerate our ability to learn about new uses for currently approved targeted anticancer drugs.
Inequalities, especially in health care, breed discontent. We need better ways to continue incentivizing the development of new drugs while optimizing access. Biosimilars help, but they won't solve the whole problem.
ASCO CEO Dr. Allen S. Lichter reflects on an optimistic approach to the challenges of providing high-quality cancer care around the globe on World Cancer Day.
Prevention is better than cure—an age-old saying, but one that is highly relevant in these times of increasing incidence of diseases and skyrocketing health care costs, notes Dr. Monica Malik.
Peer reviewers are assumed to appear fully formed, like Athena springing from Zeus’ forehead, and usually they are not required to undergo any sort of orientation. We aim to change that, in our small way, by creating the JGO Editorial Fellowship.
As physicians who take care of patients with cancer, all of us worldwide have the same goals of cancer prevention, early detection and screening, improvement in the quality of cancer care, and accelerating research and new therapies. The question is, how can we accomplish these goals in a world...

Advertisement